Ligand Pharmaceuticals announced that its senior management will participate in several investor conferences throughout May 2026, including virtual and in-person events such as the H.C. Wainwright Royalty Company Conference and the Bank of America Healthcare Conference. These appearances include fireside chats and one-on-one meetings, providing opportunities for investors to engage directly with the company. Ligand is a leading biopharma royalty aggregator with a diverse portfolio, aiming to deliver consistent revenue through strategic partnerships and licensing proprietary technologies. This active investor engagement signals Ligand's commitment to transparency and growth in the biopharmaceutical sector.
AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, co...
AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical prod...
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Replimune Group's stock fell sharply by 38.01% following FDA briefing documents that deemed its skin cancer drug trial data "not interpretable," signaling a major regulatory setback. Other companies like Travelzoo and Amkor Technology also saw signif...
Polaris Inc. reported a strong quarterly performance with earnings per share of $1.97, beating estimates by over 155%, and revenues of $2.02 billion, up 9.2% year-over-year. The growth was driven by sales recovery in the utility off-road vehicle segm...
